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ABSTRACT
Objectives To examine the public health impact of mass
vaccination with live attenuated human rotavirus vaccine
(RIX4414) in a birth cohort in India, and to estimate the
costeffectivenessandaffordability of sucha programme.
Design Decision analytical Markov model encompassing
all direct medical costs. Infection risk and severity
depended on age, number of previous infections, and
vaccination history; probabilities of use of inpatient and
outpatient health services depended on symptom
severity.
Data sources Published clinical, epidemiological, and
economic data. When possible, parameter estimates
were based on data specific for India.
PopulationSimulatedIndianbirthcohortfollowedforfive
years.
Main outcome measures Decrease in rotavirus
gastroenteritisepisodes(non-severeandsevere),deaths,
outpatient visits, and admission to hospital; incremental
cost effectiveness ratio of vaccination expressed as net
cost in 2007 rupees per life year saved.
Results In the base case, vaccination prevented 28943
(29.7%) symptomatic episodes, 6981 (38.2%) severe
episodes, 164 deaths (41.0%), 7178 (33.3%) outpatient
visits, and 812 (34.3%) admissions to hospital per
100000 children. Vaccination cost 8023 rupees (about
£100, €113, $165) per life year saved, less than India’s
percapitagrossdomesticproduct,acommoncriterionfor
cost effectiveness. The net programme cost would be
equivalent to 11.6% of the 2006-7 budget of the Indian
Department of Health and Family Welfare. Model results
were most sensitive to variations in access to outpatient
care for those with severe symptoms. If this parameter
was increased to its upper limit, the incremental cost
effectiveness ratio for vaccination still fell between one
and three times the per capita gross domestic product,
meetingtheWorldHealthOrganization’scriterionfor“cost
effective” interventions. Uncertainty analysis indicated a
94.7% probability that vaccination would be cost
effective according to a criterion of one times per capita
gross domestic product per life year saved, and a 97.8%
probability that it would be cost effective according to a
criterionofthreetimespercapitagrossdomesticproduct.
Conclusions Across a wide range of assumptions, mass
RIX4414 vaccination in India would probably prevent
substantial morbidity and mortality at a cost per life year
saved below typical thresholds of cost effectiveness. The
opportunity costs of such a programme in this or similar
settings, however, should be weighed up carefully.
INTRODUCTION
Rotavirus is the leading cause of severe gastroenteritis
worldwide,infectingvirtuallyeverychildbytheageof
5. Though the incidence of infection is similar around
the world and across economic strata,
1-7 the burden of
mortality is borne disproportionately by the world’s
poorest children.
89 Some 23% of the estimated
527000 annual rotavirus deaths occur in India.
10
The gastroenteritis caused by rotavirus tends to be
moreseverethanthatcausedbyotherviralpathogens.
The hallmark triad of fever, diarrhoea, and emesis can
bring about rapid dehydration. Indeed, severe emesis
tends to preclude the use of oral rehydration in the
most severe cases.
1112 This fact partially explains the
high rotavirus mortality in areas where access to med-
ical care is poor. Given the minimal impact that water
and sanitation measures have had on the burden of
rotavirus in developing areas, there is wide agreement
that effective vaccination represents the most promis-
ing prevention strategy against the disease.
1314
Since 2004, two new oral rotavirus vaccines have
beenintroduced:ahuman-bovinereassortantpentava-
lent rotavirus vaccine and a monovalent live attenu-
ated human rotavirus vaccine. Both vaccines seem to
stimulate protection comparable with the partial pro-
tection elicited by a single natural infection.
15-17 We
focused on live attenuated human rotavirus vaccine—
also known as RIX4414—because of the more diverse
populationinwhichitsefficacyhasbeentestedandthe
fact that a full course of RIX4414 requires only two
doses compared with the three required for the penta-
valent vaccine.
13
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trials of RIX4414 in Europe and the Americas,
151618
the extent to which the vaccine will be effective in
poorer Asian nations is unknown. A substantially
higher proportion of strains found in these areas is
genetically lesssimilar to the vaccine strainin compar-
isonwithWesterncountries,wherecompletedefficacy
trials have occurred.
1920 Two immunogenic outer cap-
sid proteins, VP7 and VP4, are used to classify rota-
viruses into G and P serotypes, respectively. These
seem to play a key (though not exclusive) role in elicit-
ing host immune responses and have been the focus in
developing existing vaccines against rotavirus. To
date, epidemiological studies have identified 42 dis-
tinct strains defined by unique G-P serotype
combinations.
21 The vaccine is derived from a G1P[8]
strain, believed to be the most common worldwide.
Globally, just four strains (G1P[8], G3P[8], G4P[8],
and G2P[4]) account for 88.5% of rotavirus diarrhoea.
Only68%ofrotaviruscasesinAsia,however,areattri-
butable to these strains.
20
Studies of both vaccines are ongoing in several
developing Asian and African countries; reporting of
thesedataisexpectedtobeginlaterin2009.
22Basedon
preliminary results, the World Health Organization
has recently recommended inclusion of rotavirus vac-
cination in these countries’ national immunisation
programmes,
23 paving the way for a spate of new rota-
virusvaccinationprogrammesinsomeofthemostvul-
nerable areas beginning as soon as 2010.
22
Accompanying concerns about the vaccine’s real
worldeffectivenessindevelopingsettingsisadaunting
set of economic challenges. The current generation of
rotavirus vaccines costs substantially more than tradi-
tional childhood vaccines given in these countries.
22
Even with manufacturers’ commitments to tiered
pricing,
24 achieving universal vaccination in the
world’s most affected areas will require substantial
help from the international community.
25 WHO has
emphasisedtheneedforthoroughexaminationofeco-
nomicissuesintheintroductionofarotavirusvaccina-
tion programme in any developing country.
26
Past models of rotavirus vaccination in developing
Asian countries
27-29 (none have been set in India) have
not captured much of the complexity of rotavirus epi-
demiology. The model we describe here differs funda-
mentally in that it simulates, in a temporally explicit
fashion,thesequenceofeventsfrominfectiontodevel-
opment of symptoms, use of health services, disease
outcome, recovery, and reinfection for a birth cohort
ofheterogeneousindividuals.Onerecentanalysisused
a similarly sophisticated epidemiological model to
examinetheimpactofvaccinationinVietnam,acoun-
try with substantially lower rates of mortality from
rotavirus and markedly different distributions of rota-
virus strain relative to India.
30 In comparison with that
model, we use methods allowing us to better predict
shifts in the mix of inpatient and outpatient care that
might result from decreased severity of symptoms
among vaccinated children who become infected.
We estimated the public health impact of mass vac-
cination with RIX4414 for a birth cohort in India and
examined the incremental cost effectiveness and
affordability of such a programme.
METHODS
Model overview
We developed an individual based Markov model,
which we analysed using Monte Carlo microsimula-
tion methods with TreeAge Pro 2008 software (Wil-
liamstown, MA). The base case evaluates only direct
medical costs, including those incurred by patients’
families or by any public sector entity contributing
toward the cost of care. In a secondary analysis from
the societal perspective, we also included direct non-
medical costs such as transportation expenses for
patients’ families and indirect costs such as foregone
wages of parents caring for sick children. The model’s
time horizon consisted of 60 one month cycles. We
assumed that administration of the vaccine would be
piggybacked on the existing WHO expanded pro-
gramme on immunisation and given concomitantly
with other routine vaccinations, including oral polio
vaccine.
31-33
Possiblestatesofindividualsinthemodelwere well,
rotavirusdiarrhoea,anddead(fig1).Attheendofeach
cycle spent in the well state, individuals faced a risk of
rotavirus infection that could be either asymptomatic
or symptomatic. Those acquiring asymptomatic infec-
tion began the nextstage ofthe model inthe wellstate,
whilethoseacquiringsymptomaticinfectionbeganthe
next stage in the rotavirus diarrhoea state. In this diar-
rhoea state, individuals experienced either severe
(Vesikariscore
34≥11)ornon-severe(score<11)symp-
toms, the probabilities of which were based on their
history of previous infections and vaccination. Symp-
tom severity influenced the likelihood that an indivi-
dual would receive inpatient, outpatient, or home
treatment. At the end of a cycle spent in the diarrhoea
state, survivors could either transition to the well state
or develop a new symptomatic rotavirus infection, re-
entering the diarrhoea state for another cycle.
Each possible chance event in the model was asso-
ciatedwithanevidencebasedprobabilityandtheexact
sequence and timing of events experienced by a given
individual were the results of random number draws
occurring at each juncture of the model. We aggre-
gated the experience of 200000 simulated individuals
to predict the expected number of rotavirus infections
(up to three per individual); their severity; the number
of admissions to hospital, clinic visits, and home treat-
ments for rotavirus gastroenteritis; the total cost of
rotavirus related use; and the number of rotavirus
related deaths under two different strategies: universal
vaccinationwithRIX4414attherecommendedagesof
2and4months
35versusnovaccination(thestatusquo).
Incidence, morbidity, and mortality
Rates of rotavirus infection (but not outcomes of infec-
tion) are similar worldwide.
836Accordingly, we chose
to base parameters related to infection risk on a
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cohort of 200 Mexican infants followed from birth to
24 months of age.
2 Velazquez and colleagues
2 closely
monitored children for rotavirus infection with serial
stool assays and serum immunoassays (a similar study
done in west Africa did not use serum immunoassays
and thus probably failed to capture a non-trivial num-
ber of infections
37). Investigators recorded the time to
first and subsequentinfections and the severityof each
infection(includingasymptomatic)foreachindividual
during follow-up. Based on the reported cumulative
incidence of the nth infection at 6, 12, and 24 month
intervals (table 1), we calculated one month hazard
rates and converted these to one month transition
probabilities corresponding to the appropriate age
interval and number of previous infections. Hazard
rates for the 12 to 24 month interval formed the basis
fortransitionprobabilityestimatesforthenthinfection
afterthe24thcycle.Figure2showsthecumulativeinci-
dence of first to the third rotavirus infection produced
by our model for children who were not vaccinated.
Data from the same cohort also served as the basis for
estimates of probabilities that those infected would
experience no symptoms, non-severe symptoms, or
severe symptoms with first to the third infections.
Severity (or lack) of symptoms did not influence the
degree of natural protection conferred against
subsequent rotavirus re-infection.
17 We varied para-
meters related to disease burden extensively in sensi-
tivity analyses.
Consistent with recent experience in India,
1138 indi-
viduals receiving formal medical attention (hospital,
clinic, or emergency department care) faced no risk
of death from rotavirus, irrespective of the severity of
gastroenteritis. We determined the model parameter
representing probability of death for those with severe
rotavirus gastroenteritis who did not receive formal
medical attention by using a simple calibration techni-
que. We varied the parameter systematically until the
model produced a five year risk of rotavirus mortality
in the no vaccination group that matched observed
rotavirus mortality in India (one in 250 children
14).
Wedidnotexplicitlyincorporateanyadditionalsurvi-
val benefit from home oral rehydration as the effect of
such treatment at prevailing levels of access and effec-
tiveness should already be implicitly reflected in the
Indian rotavirus mortality figure to which we cali-
brated. Within each cycle all individuals also faced an
agedependentprobabilityofdeathfromnon-rotavirus
causes based on published Indian life tables.
39
Vaccine characteristics
We assumedthatcoverage ratesfor dosesoneand two
of the vaccine would match rates for doses one and
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Fig 1 | Schematic of Markov model. Each individual begins life in the well state and thereafter resides in either the well,
symptomatic, or dead state during each one month cycle for a total of 60 cycles. Individuals can receive doses of live
attenuated human rotavirus vaccine at months two and four only. At the end of each cycle, each individual’s risk for rotavirus
infection is determined by number of vaccine doses received, time since receiving most recent dose, and number of previous
rotavirus infections. If infected, individuals might develop symptoms in which case they will begin the next cycle in
symptomatic state. In symptomatic state, gastroenteritis can be non-severe (Vesikari score <11) or severe (Vesikari score ≥11).
Symptom severity dictates probability that each individual will receive hospital care, outpatient care, or no formal treatment.
Those with severe disease who receive no formal treatment are at risk for death. Each month, there is an age dependent
background risk of death from non-rotavirus causes (not shown). M in circle represents Markov node; branches emanating
from a Markov node represent possible states of being. Open circle represents chance node; branches emanating to right
represent possible outcomes of probabilistic process. Left pointing triangle designates terminal node; here, the state in which
next cycle should begin is given. [+] signifies that portion of tree has been collapsed because it replicates portion already
shown. “Get dose” signifies contingency that individual receives dose of vaccine, “no dose” s i g n i f i e st h a tt h e yd on o t
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India(givenonthesamescheduleasRIX4414)(table 2
).
2231Usingapreviouslyvalidatedtechnique,
40weesti-
mated setting specific efficacy based on serotype spe-
cificefficacydata
1641andcombinedprevalencefigures
from northern,
42 eastern,
43 and southern
38 India.
Where the figures for serotype specific efficacy from
a large trial that took place almost entirely in Latin
America
16 were significant, we used these. In the case
ofG2P
4efficacy,whereresultsfromthissingletrialdid
not reach significance, we relied on data from a
recently published meta-analysis that also included
data from high income countries of Europe and
Singapore.
41 We projected that efficacy against severe
disease would be 0.804 in India (compared with 0.847
from the Latin American trial
16 and 0.958 from a trial
in six European countries
18).
In the absence of analogous serotype specific data
fromtrialsneededtoestimateefficacyagainstanyrota-
virus symptoms, we estimated this value by adjusting
our projected efficacy against severe disease by the
ratio of overall (that is, all strains) efficacy against any
symptomatic infection to overall efficacy against
severe infection from a recent phase III trial.
18 Simi-
larly, to estimate the vaccine’s efficacy against asymp-
tomatic infection in India, we adjusted the projected
vaccine efficacy against severe infection by the ratio
of efficacy against asymptomatic to severe infection
reportedly conferred by the first naturally acquired
rotavirus infection.
2
We considered the efficacy of a single dose of
RIX4414tobe37.5%lowerthanthatofafulltwodose
course.
44 The annual rate of waning of efficacy was
based on the differential between the first and second
season efficacy in a large Latin American trial
45 and
converted into monthly rates for our model.
We assumed no risk of serious adverse events for
those receiving the vaccine. An earlier tetravalent rhe-
sus recombinant rotavirus vaccine, Rotashield, was
removed from the market in 1999 after it was linked
to an increase in intussusception events among recipi-
ents in the United States.
14 The combined clinical trial
and post-marketing data pertaining to RIX4414 sug-
gest no increased rates of adverse events, including
intussusception.
46
Probabilities related to use of health services
Probabilities that symptomatic individuals would
receive inpatient care depended on the severity of
symptoms and were derived with Bayes’s formula
with the following inputs: proportion of rotavirus
inpatients in India who have severe/non-severe
Table 1 |Disease related parameters. Estimated values, ranges used in sensitivity analysis, and distribution types assumed for uncertainty analysis. Upper
and lower limits of ranges correspond to 95% confidence intervals. Standard errors used in creating probability distributions for each parameter were
estimated as quarter of range between confidence limits
56 57
Parameter Value Range Source/comments
Distribution used
in uncertainty analysis
Cumulative incidence of nth infection by 6, 12, and 24 months*:
First infection 0.34†, 0.67, 0.96 Calculated transition
probabilities varied +/− 50%
Velazquez et al
2 Normal
Second infection 0.04, 0.30, 0.69 Calculated transition
probabilities varied +/− 50%
Velazquez et al
2 Normal
Third infection 0.00, 0.07, 0.42 Calculated transition
probabilities varied +/− 50%
Velazquez et al
2 Normal
Probability that 1st, 2nd, and 3rd infections,
respectively, will cause symptoms
0.47, 0.32, 0.25 +/− 50% Velazquez et al
2 Normal
Probability that symptoms, if present, will be severe‡
(1st, 2nd, 3rd infections)
0.28, 0.19, 0.00 +/− 50% Velazquez et al
2 Normal
Probability of dying from severe rotavirus disease
without formal medical attention
0.068 0.034-0.136 Calibrated to yield known five year
rotavirusmortalityof1/250
14in“no
vaccination” group
Beta
Prevalence of rotavirus strains with:
G and P proteins in common with RIX4414 0.275 —
Composite of three recent
epidemiological studies from
Delhi,
42 Kolkata,
43 Vellore
38
—
Either G or P in common with RIX4414 0.238 ——
Neither G nor P in common with RIX4414 0.487 ——
*Hazard rate based on r = −ln(1−p) / t1 where t1 = length of interval (for example, 6 months between 6th and 12th months of life) and p = probability of infection n by end of interval given
being at risk for infection n at beginning of interval, transition probability calculated from hazard rate as p = 1 – e
-rt
2 where t2 = cycle length (one month for present model).
†Based on observation that infections by pathogenic rotavirus strains in first few months of life are rare,
11 we set probability of infection before 2 months of age to 0.
‡Severe infections are defined as those with Vesikari score ≥11.
34
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Fig 2 | Model projections for cumulative incidence of first,
second, and third rotavirus infections during first five years of
life in children receiving no vaccination
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38 five year cumulative incidence of severe/
non-severe rotavirus infection (taken directly from the
output of our model for the no vaccination strategy),
and five year cumulative probability of admission to
hospital for rotavirus. We estimated this last input at
1.55% by varying it until the model projected the
same probability of admission given any rotavirus
symptomsthatParasharetalestimatedforlowincome
countries.
8Weestimatedseveritydependentprobabil-
ities of use of outpatient services in the same manner.
Based on mean severity scores of Indian children pre-
sentingwithrotavirusinfectionininpatientversusout-
patient settings,
47 we assumed that the proportion of
outpatients whose symptoms were severe would be
half that of inpatients.
Using these inputs, we estimated the probability of
admissiongivensevereinfectionas9.7%,theprobabil-
ity of admission given non-severe infection as 0.72%,
the probability of outpatient treatment given severe
infection as 57.5%, and the probability of outpatient
treatmentgivennon-severeinfectionas14.1%(table 3).
Those not receiving any formal medical treatment
were considered to have been treated at home by the
family with a probability of oral rehydration solution
use corresponding to known levels of oral rehydration
therapy access in India.
48
Costs
Wedonotknowtheprecisecostperdosethatwouldbe
paid as part of a universal RIX4414 vaccination pro-
gramme in India. The manufacturer (GlaxoSmithK-
line) has pledged to make the vaccine available at
greatly reduced prices to public sector programmes
in lower income countries.
24 The manufacturer
recently sold millions of doses to the government of
Brazil at a cost of $7 (£4, €4.8) per dose.
24 We used
thisfigure(convertedto2007rupees)asabaselineesti-
mateforthevaccine’scostandvarieditsubstantiallyin
sensitivity analysis (table 3). We also do not know the
degree of increase in administration costs that would
be incurred by adding RIX4414 to the existing vacci-
nation schedule. Consistent with other
investigators,
2829 we applied an administration cost
equivalent to $0.50 a dose. We also varied this value
over a widerange,givendoubtsaboutthe adequacyof
many poorer countries’ cold chain infrastructure to
accommodate the added volume of a bulky new oral
vaccine.
25 We assumed a standard 10% rate of vaccine
wastage.
272849
We were fortunate to have recent data on direct
medical, direct non-medical, and indirect costs from a
studyoftheeconomicburdenofrotavirustreatmentin
Vellore,India.
47BasedonWHOguidelinesforgather-
ingcostdataontreatmentofdiarrhoea,
50theinvestiga-
tors followed hospital, clinic, and emergency
department patients (we combined the latter two cate-
gories into one“outpatient” category) prospectively in
three facilities serving markedly different populations
of patients. We weighted the costs reported for each
treatment setting (inpatient or outpatient) at each facil-
ity by the reported number of encounters in each set-
ting and facility to estimate average costs for inpatient
and outpatient treatment.
Cost effectiveness analysis
Wedeterminedtheincrementalcosteffectivenessratio
for moving from a strategy of no vaccination to a strat-
egy of universal two dose vaccination with RIX4414.
For the base case analysis, this ratio was expressed in
2007 Indian rupees per life year saved and was calcu-
lated as the difference in mean cost under the vaccina-
tion strategy compared with that under the no
vaccination strategy divided by the difference in
years of life lost between the two strategies. Costs and
benefits were discounted at a standard annual rate of
3%, consistent with previous analyses.
28294951 In a sec-
ondary analysis, we calculated the incremental cost
effectivenessin termsofdiscountedrupeesperdisabil-
ity adjusted life year (DALY) averted (by using stan-
dard age weighting and discounting
52). Based on the
Table 2 |Vaccine related parameters. Estimated values, ranges used in sensitivity analysis, and distribution types assumed for uncertainty analysis. Upper
and lower limits of ranges correspond to estimates of 95% confidence intervals. Standard errors used in creating probability distributions for each
parameter were estimated as quarter of range between confidence limits
56 57
Parameter Value (range) Source/comments
Distribution used
in uncertainty analysis
Coverage for dose 1 (age 2 months) 0.81 (0.71 to 0.91) Based on DPT-1 coverage
31 β
Coverage for dose 2 (age 4 months) 0.77 (0.67 to 0.87) Based on DPT-3 coverage
31 β
Efficacy against severe infection caused by rotavirus strains with:
G and P proteins in common with RIX4414 0.908 (0.705 to 0.982*) Ruiz-Palacios et al
16 β
Either G or P in common with RIX4414 0.869 (0.628 to 0.966*) Ruiz-Palacios et al
16 β
Neither G nor P in common with RIX4414 0.714 (0.201 to 0.911*) De Vos et al
41 β
Ratio of efficacy against any symptomatic rotavirus infection
to efficacy against severe infection
0.873 (0.773 to 0.973) Vesikari et al
18 β
Ratio of efficacy against asymptomatic infection to efficacy
against severe infection
0.437 (0.337 to 0.537) Velazquez et al
2 β
Proportion of full efficacy conferred by single dose 0.625 (0.425 to 0.825) Lopez et al
44 β
Assumed annual rate of waning in vaccine efficacy 0.049 (0.0 to 0.10) Based on decline in efficacy between 1st
and2ndseasonsintwoyeartrialinLatinAmerica
45
β
*Ranges based on actual 95% confidence intervals from trial data.
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the Global Burden of Disease Study
53 and a typical
durationofsymptomsofoneweek,
19weusedadisabil-
ity weight of 0.0023 per symptomatic episode.
Often,athresholdofone
284951totwo
54timesacoun-
try’s per capita gross domestic product is used as a cri-
terion to gauge whether the incremental cost of an
intervention per life year saved or per DALY averted
can be considered sufficiently cost effective. WHO
describes interventions costing less than a country’s
per capita gross domestic product per DALY averted
as “very cost effective” and those costing between one
and three times per capita gross domestic product as
“cost effective.”
55 Though our main cost effectiveness
measure was cost per life year saved—not per DALY
averted—we chose a threshold of one times per capita
grossdomesticproduct.Thisapproachisslightlymore
conservative than basing the threshold on DALYs
averted as life years saved do not capture the non-
financial benefits of reducing symptoms in non-fatal
cases.
51
Sensitivity and uncertainty analyses
To assess the overall robustness of our model and to
identifyinfluentialparametersforwhichbetterempiri-
cal data are needed, we performed one way sensitivity
analyses by individually varying each input parameter
across the ranges shown in the tables.
To help us gauge the overall impact of parameter
uncertainty, we also performed a type of uncertainty
analysis, known as two dimensional probabilistic sen-
sitivity analysis, by creating probability distributions
for nearly all parameters in the model. For estimates
ofadministrationcostsandforcostofthevaccineitself,
we applied triangular distributions with limits of 50%
and 300%, and 50% and 200%, respectively. For all
other costs, we used normal distributions with 95%
confidence intervals equal to plus or minus 25% of
the mean. We inserted three separate constants (each
with a base value of 1.0) in our model, which, when
varied, affected the calculated transition probabilities
for nth infection, the probabilities that infection n
would cause symptoms, and the probabilities that
symptoms of infection n, if present, would be severe.
Table 3 |Utilisation and cost parameters. Estimated values, ranges used in sensitivity analysis, and distribution types
assumed for uncertainty analysis. Upper and lower limits of ranges correspond to estimates of 95% confidence intervals.
Standard errors used in creating probability distributions for each parameter were estimated as quarter of range between
confidence limits
56 57
Parameter Value (range) Source/comments
Distribution used
in uncertainty analysis
Probabilities related to use of health services
Probability of admission to hospital given:
Non-severe infection 0.00721 (0.00361 to 0.0108) Calculated based on
83 8 * β
Severe infection 0.0973 (0.0487 to 0.146) Calculated based on
83 8 * β
Probability of outpatient treatment given:
Non-severe infection 0.141 (0.0705 to 0.212) Calculated based on
83 8 * β
Severe infection 0.575 (0.288 to 0.863) Calculated based on
83 8 * β
Probabilityofaccesstooralrehydrationsolutionat
home
0.30 (0.0 to 1.0) Jain et al
48 β
Costs (in 2007 rupees)† †
Cost of one dose of RIX4414 285.2 (142.6 to 570.4) Based on price paid by Brazilian
government
25
Triangular
Cost of administering vaccine (per dose) 20.4 (10.2 to 81.6) Podewils et al,
28 Isakbaeva et al
29 Triangular
Hospital treatment of rotavirus infection:
Direct medical:
Paid by patient’s family 2444.3 (1833.2 to 3055.4) Mendelsohn et al
47 Normal
Subsidised by government 189.4 (142.1 to 236.8) Mendelsohn et al
47 Normal
Direct non-medical 39.9 (29.9 to 49.9) Mendelsohn et al
47 Normal
Indirect 0 Mendelsohn et al
47 NA
Outpatient treatment of rotavirus infection:
Direct medical:
Paid by patient’s family 156.2 (117.2 to 195.3) Mendelsohn et al
47 Normal
Subsidised by government 52.1 (39.1 to 65.1) Mendelsohn et al
47 Normal
Direct non-medical 23.6 (17.7 to 29.5) Mendelsohn et al
47 Normal
Indirect 1.8 (1.4 to 2.3) Mendelsohn et al
47 Normal
Oral rehydration solution (per course) 15.4 (11.3 to 18.8) Patel et al
80 Normal
Discount rates — —
For costs 3% (0% to 3%) ——
For benefits 3% (0% to 3%) ——
NA=not applicable.
*General formula: p(site severity) = [p(severity site) * p(site)]/p(severity).
†In 2007 1 rupee = $0.025.
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tributionwith95%confidencelimitsof0.5and1.5.For
all other proportions and probabilities, we used β dis-
tributions with α and β parameters estimated from
mean and standard error. We estimated standard
errors based on the approximation that lower and
upper limits usedin one way sensitivityanalysisrepre-
sented 95% confidence limits, with ranges equal to
approximately four times the standard error.
5657 One
thousand probabilistically sampled parameter sets (a
typical number in decision analyses
58-61) were each
used to simulate a cohort of 100000 individuals. We
thencalculatedtheproportionofthese1000samplings
that would have produced results considered cost
effective.
RESULTS
Base case
The model predicted that, without vaccination, essen-
tially all children would have had a first infection by
60 months of age (consistent with conventional
wisdom
81362), 98.6% would have had a second infec-
tion, and 94.4% would have had a third infection
(fig2).Table 4showstheprojectednumbersofclinical
events and use of health services per 100000 children
followed for five years under both strategies. Based on
an actual Indian birth cohort size of about 25 million a
year,
63 each year vaccination would be expected to
prevent 1745000 severe episodes of gastroenteritis,
1794500 outpatient visits, 203000 admissions to hos-
pital, and 41000 deaths among children younger than
5 years.
The additionaldirect medicalcost incurredby mov-
ingfromnovaccinationtothevaccinationstrategy(net
of any savings from reduced expenditures for treat-
ment) would be 432.4 rupees (about £5, €6, $9) per
person. On average, vaccination would be expected
tosave0.05390lifeyearsperperson,yieldinganincre-
mentalcosteffectivenessratioof8023rupees(orabout
£100, €113, $164) per life years saved (table 5). The
intervention would thus satisfy our cost effectiveness
criterion of less than India’s per capita gross domestic
product (37907 rupees in 2007
64) per life year saved.
Takingthebroadersocietalperspective,theincremen-
talcosteffectivenessratiowas7984rupeesperlifeyear
saved. With DALYs averted as an alternative measure
of effectiveness, the ratio was 6552 rupees per DALY
averted.
Sensitivity analysis
In a sensitivity analysis, increasing the coverage level
for the first and second doses of the vaccine by 10 per-
centagepointsincreasedthereductioninmortalitydue
to vaccination from 41.1% to 47.6%, saving an addi-
tional 6500 lives annually population-wide. We also
examined the impact of vaccination under a scenario
of low efficacy in which each strain specific efficacy
figure shown in table 2 was reduced by 15 percentage
points.Even at thissubstantially reducedefficacy, vac-
cination could still be expected to save 26750 lives in
one year with an incremental cost effectiveness of
11647 rupees per life year saved.
Figure 3 shows the individual parameters which,
when varied across their full ranges, most affected the
incremental cost effectiveness ratio from baseline.
Increasing the probability that children with severe
symptoms would present for outpatient treatment by
50% increased the ratio to 51637 rupees per life year
saved, an effect driven mainly by a 92% reduction in
mortality that was independent of vaccination status.
This was the only individual parameter capable of
increasing the incremental cost effectiveness ratio
above per capita gross domestic product. There is
marked asymmetry of results for parameters which,
when varied, would affect individuals in both the vac-
cination and no vaccination groups. In each of these
cases, changes that lessen the morbidity or mortality
of disease reduce the cost effectiveness of vaccination
(resulting in higher incremental cost effectiveness
ratios). When disease is less serious, the potential mar-
ginal healthbenefitof vaccination(thedenominatorof
theincrementalcosteffectivenessratio)becomessmal-
ler. Meanwhile, marginal cost in the numerator tends
to increasewithless seriousdisease assavingsontreat-
ment costs due to vaccination become more modest.
We explored a scenario in which the overall infec-
tionrate,probabilityofsymptomsgiveninfection,and
probability that any symptoms would be severe were
simultaneously increased by 50%. In this scenario of
higher disease burden, absolute mortality reduction
per 100000 due to vaccination rose from 164 to 310
lives, while the incremental cost effectiveness fell to
5007 rupees per life year saved.
Alternative discountrates of0% forcosts and 0% for
health benefits yielded an incremental cost
Table 4 |Expected clinical events and use of health services related to rotavirus infection in
birth cohort of 100 000 Indian infants followed for five years under strategies of no
vaccination and vaccination with RIX4414
No vaccination Vaccination Change (%)
Clinical events per 100 000 children
Any infection 278 672 253 657 −25 015 (−9.0)
Asymptomatic infections 181 164 185 092 3928 (2.2)
Symptomatic infections 97 508 68 565 −28 943 (−29.7)
Severe infections 18 260 11 279 −6981 (−38.2)
Deaths 398 235 −163 (−41.0)
Use of health services per 100 000 children
Home treatment with oral rehydration solution 73 221 52 191 −21 030 (−28.7)
Outpatient visits 21 582 14 405 −7177 (−33.3)
Admissions to hospital 2367 1555 −812 (−34.3)
Table 5 |Base case cost effectiveness results: strategy of no vaccination compared with
strategy of vaccination with two doses of RIX4414
Mean cost
(2007 rupees) Marginal cost
Mean years
of life lost
Life years
saved (LYS)
ICER*
(rupees/LYS)
No vaccination 106.5 — 2.06627 ——
Vaccination 538.9 432.4 2.01237 0.05390 8023
*Incremental cost effectiveness ratio (ICER) calculated as marginal cost in 2007 rupees divided by life years
saved.
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whileratesof3%forcostsand0%forbenefitsyieldeda
ratio of 3586 rupees per life year saved.
Figure 4 shows an acceptability curve summarising
the results of our uncertainty analysis. The model was
run 1000 times, each time with a different probabilisti-
cally sampled parameter set. In 94.7% of those runs,
the cost effectiveness ratio for vaccination fell below
per capita gross domestic product, our conservative
criterion for cost effectiveness. In 97.8% of model
runs, the ratio fell below three times per capita gross
domesticproduct(thelevel belowwhichinterventions
are considered “cost effective”by WHO guidelines
55).
DISCUSSION
The results of this study suggest that universal
RIX4414 vaccination in India would save many thou-
sandsoflivesannuallyacrossawiderangeofscenarios.
Inthebasecaseanalysis,weprojectedthatvaccination
would annually prevent 1745000 severe episodes of
gastroenteritis, 1794500 outpatient visits, 203000
admissions to hospital, and 41000 deaths among
Indian children below the age of 5 at a cost of 8023
rupees (about £100, €113, S165) per life year saved.
Theprojectedreductioninmortalitywasheavilyinflu-
enced by changes in levels of vaccine coverage, vac-
cine efficacy, and probability that a severely ill child
would receive outpatient care. While incremental
cost effectiveness was sensitive to changes in probabil-
ity of use of outpatient services for those with severe
symptoms, parameters influencing disease severity,
vaccine cost, case fatality rate, and vaccine efficacy,
no scenario in our deterministic sensitivity analysis
yielded an incremental cost effectiveness ratio greater
thanthreetimesthepercapitagrossdomesticproduct.
Only one parameter, when varied to its upper limits,
pushed the incremental cost effectiveness ratio above
one times the per capita gross domestic product: the
probability of outpatient care for the severely sympto-
matic of 0.863 (versus 0.575 in the base case). Under-
lying this large effect was the fact that improved access
to care greatly reduced baseline rotavirus mortality,
diminishing the potential mortality benefit of vaccina-
tion. Uncertainty analysis suggested that, given the
combined extent of uncertainty in all parameter esti-
mates, vaccination would satisfy a conservative one
times per capita gross domestic product criterion for
cost effectiveness with 94.7% probability. Further-
more, it would satisfy WHO’s three times the per
capita gross domestic product criterion with 97.8%
probability.
Strengths of study
This study features several methodological strengths.
The model simulates clinical events and use of health
services in a temporally explicit fashion that incorpo-
rates the changing effects of each individual’s age,
infection history, and vaccination history on infection
risk and response to infection. Vaccine efficacy is
adjusted to account for distributions of strains specific
to India. Monthly probabilities of infection are based
on hazard rates calculated from a meticulously
executed birth cohort study, which captured even
asymptomatic infections. Use of such complete epide-
miological data in a model of rotavirus infection is
important given the role of asymptomatic infections
in reducing risk and severity of future infections. In
addition, the study benefited from the availability of
recent cost data.
47
We found no previously published analyses that
examined the impact of rotavirus vaccination specifi-
cally in India. A study by Podewils et al published in
2005examinedthecosteffectivenessofvaccinationfor
low income Asian countries.
28 We consider, though,
that these investigators might have substantially over-
estimated the incidence of admission to hospital, lead-
ing to significant overestimation of cost savings from
vaccination. They applied a one year cumulative inci-
dence of admission for rotavirus among children aged
0-60 months
11 to a hypothetical cohort of infants fol-
lowed for five years by simply multiplying the inci-
dence by five. If the closed group of children aged
0-60 months in the source study had been followed
for subsequent years, however, much lower rates of
0 10 000 20 000 30 000 40 000 50 000
Probability that infection will cause
  symptoms
Efficacy of RIX4414 against non-G1,
  non-P[8] strains
Probability of dying from severe
  infection if untreated
Vaccine cost per dose (rupees)
Probability that symptoms, if present,
  will be severe
Probability that child with severe
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ICER (rupees/LYS)
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Fig 3 | Individual parameters with greatest influence on incremental cost effectiveness ratio,
expressed in rupees per life year saved (LYS), in univariate sensitivity analysis. Solid vertical
line represents base case incremental cost effectiveness ratio of 8023 rupees per life year
saved
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Fig 4 | Acceptability curve for strategy of vaccination with live
attenuated human rotavirus vaccine (RIX4414) compared with
no rotavirus vaccination. Curve represents probability that
vaccination would be cost effective over range of threshold
incremental cost effectiveness ratios (ICERs)
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gested by the fact that 98% of admissions in the source
study occurred in children younger than 24 months.
11
Kim et al recently published an analysis of rotavirus
vaccination in Vietnam.
30 Though not individual
based, their model shares some key features with
ours, including acquired partial immunity from past
infections and the possibility of multiple rotavirus
infections. The authors also drew several epidemiolo-
gical parameters from the Velazquez birth cohort
study of Mexican infants.
2 They assumed that deaths
related to rotavirus, admissions to hospital, and outpa-
tient visits all decrease in proportion to one another
under vaccination. This approach fails to take into
account the effects of decreased severity of symptoms
on relative rates of use of inpatient and outpatient ser-
vices. Because we modelled the effects of vaccination
on severity of symptoms and the effects of severity on
probabilitiesofserviceuseinspecificsettings,wecould
simulate the shift toward lower levels of care needed
for children with rotavirus disease under vaccination
(that is, larger decreases in admissions than in outpati-
ent visits).
With their modelKim et al examinedvaccination in
a setting with a rate of rotavirus mortality substantially
lower than that seen in India.
30 This limits the applic-
ability of their findings for countries that, like India,
have the highest rates of rotavirus mortality.
1422 Para-
meters specific to these other high mortality countries
(vaccine coverage rates, rates of service use, costs, etc)
would differ from those in India. The consistency of
our model’s conclusions over wide ranges of para-
meter inputs in sensitivity analysis suggests that vacci-
nation would probably offer enormous public health
benefit in many of these settings.
Irrespective of cost effectiveness, a public health
intervention must also be affordable. Net of savings
from reduced expenditures on subsidised treatment,
we calculated that universal RIX4414 vaccination
would cost the Indian Department of Health and
Family Welfare 11.6bn rupees (about £140m, €160m,
$240m) annually or, for context, about 11.6% of that
department’s 2006-7 budget.
65 Whether this level of
cost is acceptable is a decision to be made by country
officialsand the internationalorganisationsthat would
helpfinancemassvaccination.Fortunately,lessexpen-
siverotavirusvaccinesmightbejustafewyearsawayif
theeffortsofsomeIndianfirmsandofficialsinpartner-
shipwiththe NationalInstitutesofHealth,theCenters
for Disease Control and Prevention, and the Program
for Appropriate Technology in Health are successful.
Theseagenciesaresupportingthedevelopmentofcan-
didate rotavirus vaccines based on native strains to be
manufactured and used in some developing Asian
countries, including India.
192425 Currently, the
diphtheria-tetanus-pertussis and hepatitis B vaccines
used in India are produced domestically for less than
$1 a dose.
66 Officials with a company hoping to manu-
factureIndia’sfirsthomegrownrotavirusvaccinehave
likewise set a goal of producing the agent for $1 a
dose.
67 According to our model, a universal rotavirus
vaccination programme with a per dose cost equiva-
lent to $1 would cost 1644 rupees (£20, €23, $34) per
life year saved, with a total annual cost equal to about
2.2% of the 2006-7 Indian Department of Health and
FamilyWelfare’sbudget.Thisfiguredoesnottakeinto
account possible benefits of improved efficacy pro-
vided by a vaccine derived from native strains.
We compared universal rotavirus vaccination to the
status quo of no rotavirus vaccination. Future analyses
shouldcomparethe cost effectivenessofrotavirus vac-
cinationwithpossiblestrategiesusingotherlessexpen-
sive but underused interventions to reduce child
mortality. One such intervention might be expansion
of micronutrient supplementation and fortification
programmes. In India, deficiencies of micronutrients
are reportedly associated with more deaths than rota-
virus, with around 330000 child deaths each year
attributed to vitamin A deficiency alone.
68 Despite
this, supplementation and fortification programmes
remain inadequate.
6869
Limitations
Whenever possible, we based parameter estimates on
data specific for India. Incidence and severity (but not
service use or mortality) parameters in our model,
however, were based on the results of a Mexican
birth cohort study.
2 Evidence suggests that incidence
rates of rotavirus infection are similar worldwide and
across economic strata
1-7 and that survival is largely a
function of access to medical care.
1138 It is reasonable
toexpectthoughthataveragesymptomseveritymight
be greater in poorer countries, where underlying
health tends to be worse, compared with severity in
anuppermiddleincome
70countrylikeMexico.Insen-
sitivity analysis, we showed that any potential under-
estimation of disease burden would bias the analysis
against the intervention. Vaccination would become
twice as cost effective if infection rates, probability
that infections were symptomatic, and probability
that any symptoms were severe were all simulta-
neously increased by 50%. Less apparent is the direc-
tion of any mis-specification of severity dependent
probabilities of service use. Because these types of
data were not directly available in the published litera-
ture, we were forced to make inferences based partly
on data specific to India
38 and partly on previous esti-
matesofrotavirusrelateduseofhealthservicesininpa-
tientandoutpatientsettingsfordevelopingcountriesin
general.
8 In particular, the model’s conclusions were
sensitive to variation in the probability that those
with severe rotavirus disease would receive outpatient
care.Intheextreme,increasingthisprobabilityby50%
(from 0.575 to 0.863) would result in an incremental
cost effectiveness ratio equivalent to about 1.4 times
India’s per capita gross domestic product, falling
between the WHO’s criteria for “very cost effective”
(onetimespercapitagrossdomesticproduct)and“cost
effective” (three times per capita gross domestic pro-
duct) interventions.
55
Earlier live oral vaccines against rotavirus,
71-74 as
well as those against cholera
75-77 and polio,
7879 have
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 9 of 12historicallyperformedlesswellthanexpectedindevel-
oping Asian and African countries. Some believe this
might be because of differences in nutrition and coin-
fecting pathogens.
141924 Our model does not account
forthisdirectly.Inadditiontoaccountingforincreased
strain diversity, however, we performed a sensitivity
analysis that showed that even with efficacy that was
15 percentage points lower against all strains, the vac-
cine could still save 26750 Indian infants in a one year
birth cohort and would remain similarly cost effective
(11647 rupees per life year saved).
Finally,aswithpreviouslypublishedmodelsofrota-
virus vaccination, we did not take into account effects
of herd immunity or declines in vaccine efficacy over
time because of vaccination induced strain replace-
ment.
Conclusion
Rotavirus vaccination with RIX4414 in India would
prevent a substantial portion of rotavirus related mor-
bidity,mortality,anduseofhealthservicesatacostper
life year saved that would easily satisfy criteria for cost
effectiveness. With WHO having recently extended
their recommendation for rotavirus vaccination to
developing Asian and African countries, implementa-
tion of mass vaccination programmes in these areas
could begin soon, with benefits starting to accrue in a
relatively short time. Even with steeply tiered pricing,
though, the vaccine will probably be expensive by
developing world standards. For this reason, we
believe that any programme of vaccination with
RIX4414 or other rotavirus vaccines with comparable
costandefficacyshouldbeviewedasonlyatemporary
solution until less expensive vaccines derived from
native strains can be manufactured regionally. Rota-
virus is only one member of a long list of killers in the
developing world. Further analyses should compare
vaccination with other, less expensive interventions
such as expansion of micronutrient supplementation
and fortification programmes to make certain that the
most cost effective solutions do not go unexploited.
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